Education
About Us
Working with TipRanks
Follow Us
Aardvark Therapeutics, Inc. (AARD)
NASDAQ:AARD
AARD Stock Chart & Stats
$11.69
--
Market closed
$11.69
--
Day’s Range― - ―
52-Week Range$4.88 - $19.58
Previous CloseN/A
VolumeN/A
Average Volume (3M)215.13K
Market Cap
$266.44M
Enterprise Value$152.11M
Total Cash (Recent Filing)$141.82M
Total Debt (Recent Filing)$645.00K
Price to Earnings (P/E)―
Beta1.43
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding21,696,894
10 Day Avg. Volume163,213
30 Day Avg. Volume215,128
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.65K
Enterprise Value/Ebitda-3.73
Forecast
1Y Price Target
$31.43Price Target Upside168.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsAardvark Therapeutics is focusing on treating obesity and hyperphagia with its clinical-stage biotech innovations, with ARD-101 showing potential in addressing a significant unmet medical need.
Financial StabilityThe cash position of $141.8M ensures financial stability for Aardvark, providing a runway into 2027.
Market PotentialThe launch of Vykat underscores the high demand for Prader Willi Syndrome treatments, suggesting a positive commercial outlook for Aardvark's ARD-101.
Bears Say
Clinical Trial RisksDespite optimism, there is a risk that the trial could fail simply by chance due to the challenging nature of Prader-Willi Syndrome.
Imperfections In DataBoth the clinical data and the mechanism/biology behind ARD-101 are considered imperfect and present real risk.
Aardvark Therapeutics, Inc. News
AARD FAQ
What was Aardvark Therapeutics, Inc.’s price range in the past 12 months?
Aardvark Therapeutics, Inc. lowest stock price was $4.88 and its highest was $19.58 in the past 12 months.
What is Aardvark Therapeutics, Inc.’s market cap?
Aardvark Therapeutics, Inc.’s market cap is $266.44M.
When is Aardvark Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aardvark Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Aardvark Therapeutics, Inc. overvalued?
According to Wall Street analysts Aardvark Therapeutics, Inc.’s price is currently Undervalued.
Does Aardvark Therapeutics, Inc. pay dividends?
Aardvark Therapeutics, Inc. does not currently pay dividends.
What is Aardvark Therapeutics, Inc.’s EPS estimate?
Aardvark Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aardvark Therapeutics, Inc. have?
Aardvark Therapeutics, Inc. has 21,696,894 shares outstanding.
What happened to Aardvark Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aardvark Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AARD
Aardvark Therapeutics, Inc. Stock Smart Score
Company Description
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. (AARD) is a biotechnology company focused on developing innovative therapies for metabolic and inflammatory diseases. The company specializes in creating and advancing novel treatments aimed at addressing unmet medical needs in these sectors. Its core products include proprietary drug candidates designed to modulate metabolic pathways and reduce inflammation, ultimately improving patient outcomes and quality of life.
AARD Stock 12 Month Forecast
Average Price Target
$31.43
▲(168.86% Upside)
Technical Analysis
Annexon Biosciences
―
Nanobiotix
―
Alpha Tau Medical Ltd
―
OmniAb
―
Third Harmonic Bio, Inc.
―
Ownership Overview
42.52% Insiders
2.62% Mutual Funds
28.78% Other Institutional Investors
23.25% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---